GlassScriptPhysician profile
Ahmad Z Sheikh
NPI 1609086180
$7,377.85
in general payments reported to CMS, 2019-2025
35 companies · $1,368 in 2025
The $1,368 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,831 · 2020: $281 · 2021: $124 · 2022: $550 · 2023: $1,579 · 2024: $1,646 · 2025: $1,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,571 · Education: $21.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,570.57 |
| Education | $21.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,321.65 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $893.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $592.40 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Insulet Corporation | $439.23 | 2019-2025 | Omnipod |
| Abbott Laboratories | $433.61 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $417.99 | 2019-2024 | |
| Abbvie INC. | $312.89 | 2019-2025 | Synthroid |
| Corcept Therapeutics | $308.67 | 2020-2024 | Korlym |
| Novartis Pharmaceuticals Corporation | $268.01 | 2019-2024 | |
| Medtronic, INC. | $215.73 | 2023-2025 | Minimed 780g, Inceptiv |
| Dexcom, INC. | $195.69 | 2019-2025 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $178.21 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Radius Health, INC. | $177.37 | 2024-2025 | Tymlos |
| Lilly USA, LLC | $175.69 | 2019-2025 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $140.50 | 2022-2025 | Recorlev, Gvoke Hypopen |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.